Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer

Ann Oncol. 2022 Mar;33(3):350-352. doi: 10.1016/j.annonc.2021.11.015. Epub 2021 Nov 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19*
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antibodies, Viral
  • BNT162 Vaccine